HIVandHepatitis.com
HIVandHepatitis.com
Risk of Reinfection Is a Concern After Successful Hepatitis C Treatment

People on opiate agonist substitution therapy can be successfully treated with grazoprevir/elbasvir (Zepatier) -- achieving cure rates similar to those of the population as a whole -- but some people are reinfected with hepatitis C virus after being cured, suggesting that a greater emphasis on post-treatment prevention may be needed, according to presentations at the 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016) this month in Oslo.

HIVandHepatitis.com
HCV Treatment Effective and May Work as Prevention for People Who Inject Drugs

Hepatitis C treatment for people who inject drugs is as safe and effective as it is for non-drug-users -- with cure rates exceeding 90% -- and treating enough of this population could reduce transmission or even bring a halt to local epidemics, according to presentations at the 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016) last week in Oslo.

HIVandHepatitis.com
Hepatitis C Vaccine Development Shows Progress but Scientific Barriers Remain

An effective vaccine may be necessary to eliminate hepatitis C virus (HCV), but development has been hampered by several challenges including the variability of the virus and incomplete natural immunity, according to presentations at the 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016) last week in Oslo. One promising prime-boost viral vector vaccine is currently in clinical trials.

 

HIVandHepatitis.com
Effective Antiviral Treatment Reduces Fatigue in People with Hepatitis C

Fatigue -- a common symptom among people living with hepatitis C virus (HCV) infection -- is associated with liver inflammation and fibrosis, but antiviral therapy that leads to a cure significantly reduces the likelihood of fatigue, according to a Danish study presented at the 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016) this week in Oslo.

HIVandHepatitis.com
Opens with Focus on Hepatitis C Prevention and Treatment for People Who Inject Drugs

The 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016) got underway Wednesday with an overview of the epidemiology of hepatitis C virus (HCV) among people who inject drugs and a look at public health and harm reduction approaches to preventing, treating, and managing hepatitis C in this often neglected population.

 

HIVandHepatitis.com
Scaling Up Treatment in Prisons Could Help Halt Hepatitis C Epidemics

A substantial proportion of people with hepatitis C cycle through the criminal justice system, making prisons one of the most important settings for hepatitis C virus (HCV) prevention, testing, and treatment. Scaling up treatment could therefore play a major role in driving down HCV prevalence and curbing hepatitis C epidemics worldwide, according to studies presented at the 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016) this week in Oslo.